Challenges of Cancer Immunotherapy during the COVID-19 Pandemic.
Publication
, Journal Article
Kuderer, NM; Lyman, GH
Published in: Cancer Invest
February 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
February 2021
Volume
39
Issue
2
Start / End Page
115 / 119
Location
England
Related Subject Headings
- SARS-CoV-2
- Pandemics
- Oncology & Carcinogenesis
- Neoplasms
- Medical Oncology
- Immunotherapy
- Humans
- Comprehensive Health Care
- COVID-19
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Kuderer, N. M., & Lyman, G. H. (2021). Challenges of Cancer Immunotherapy during the COVID-19 Pandemic. Cancer Invest, 39(2), 115–119. https://doi.org/10.1080/07357907.2020.1864129
Kuderer, Nicole M., and Gary H. Lyman. “Challenges of Cancer Immunotherapy during the COVID-19 Pandemic.” Cancer Invest 39, no. 2 (February 2021): 115–19. https://doi.org/10.1080/07357907.2020.1864129.
Kuderer NM, Lyman GH. Challenges of Cancer Immunotherapy during the COVID-19 Pandemic. Cancer Invest. 2021 Feb;39(2):115–9.
Kuderer, Nicole M., and Gary H. Lyman. “Challenges of Cancer Immunotherapy during the COVID-19 Pandemic.” Cancer Invest, vol. 39, no. 2, Feb. 2021, pp. 115–19. Pubmed, doi:10.1080/07357907.2020.1864129.
Kuderer NM, Lyman GH. Challenges of Cancer Immunotherapy during the COVID-19 Pandemic. Cancer Invest. 2021 Feb;39(2):115–119.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
February 2021
Volume
39
Issue
2
Start / End Page
115 / 119
Location
England
Related Subject Headings
- SARS-CoV-2
- Pandemics
- Oncology & Carcinogenesis
- Neoplasms
- Medical Oncology
- Immunotherapy
- Humans
- Comprehensive Health Care
- COVID-19
- 3211 Oncology and carcinogenesis